US · Healthcare · Drug Manufacturers - General
EPS came in at 6.45 against a street estimate of 5.74 — a beat of 12.4%.
Analysts rate Amgen Inc a hold (12 buy, 17 hold, 5 sell out of 34) with an average price target of $404.32.
CONFIDENT Q2 beat on revenue (+10% YoY to $10.05B) and earnings. Six growth drivers up 26% YoY, now 70% of sales. Raised FY26 guidance above street. Pipeline progressing: MariTide, Olpasiran, IMDELLTRA expanding into earlier lines. Q2 2026 US dominates growth drivers; Japan and Europe expanding methodically with EVENITY and BLINCYTO leading international momentum. Analysts pressed competitive threats (Merck oral PCSK9, pelacarsen Lp(a), SOTYKTU dermatology), trial design choices (Olpasiran MACE-3, dazodalibep symptomatic endpoints), and operational feasibility (IMDELLTRA monitoring, MariTide dosing flexibility). Management emphasized data superiority, regulatory acumen, and real-world execution ability. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.13% |
| Vanguard Capital Management, LLC | 6.52% |
| State Street Corp | 5.65% |
| Capital World Investors | 5.38% |
| Amvescap Plc. | 3.02% |
| Geode Capital Management, LLC | 2.90% |
| Charles Schwab Investment Management Inc | 2.78% |
| Vanguard Portfolio Management, LLC | 2.75% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 revenue was $10,365 million, up from $9,557 million in the third quarter of 2025. • Nine-month 2026 revenue wa | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Q3 2026 revenue increased 8% year over year to $10.4 billion, with product sales also up 8% to $9,883 million. • GAAP EPS increas | 2026-11-03 |
| Board / officer change · Q4 2026 OTHER NOTABLE POINTS • Amgen appointed David W. Gibbs to its Board of Directors effective October 26, 2026. • Gibbs served as Chief Executive Office | 2026-10-27 |
| Quarterly report · Q2 2026 AMGEN INC. – FORM 10-Q SUMMARY FOR RETAIL INVESTORS Quarter ended June 30, 2026 --- HEADLINE NUMBERS • Q2 2026 net income: $2,375 million (vs. $1,4 | 2026-08-05 |
| Results announced · Q3 2026 AMGEN Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenues increased 10% to $10.1 billion in Q2 2026 vs Q2 2025 • Product sales grew 9% to $9. | 2026-08-04 |
| Current report · Q3 2026 AMGEN INC. – 8-K SUMMARY (July 29, 2026) HEADLINE NUMBERS • No financial impact quantified in this filing • Company states incident is "not reasonabl | 2026-07-31 |
| Shareholder vote results · Q2 2026 AMGEN INC. - 8-K FILING SUMMARY Date of Report: May 19, 2026 --- HEADLINE NUMBERS • Annual Shareholder Meeting held May 19, 2026 • Total votes cast | 2026-05-20 |
| Board / officer change · Q2 2026 AMGEN INC. - 8-K SUMMARY (MAY 19, 2026) HEADLINE NUMBERS • Peter H. Griffith retiring as Chief Financial Officer effective August 31, 2026, followed | 2026-05-19 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $2.52 / share ex-date Nov 20, 2026 · pay Dec 11, 2026 | 2026-11-20 |
| Dividend | $2.52 / share ex-date Aug 21, 2026 · pay Sep 11, 2026 | 2026-08-21 |
| Dividend | $2.52 / share ex-date May 15, 2026 · pay Jun 5, 2026 | 2026-05-15 |
| Dividend | $2.52 / share ex-date Feb 13, 2026 · pay Mar 6, 2026 | 2026-02-13 |
| Dividend | $2.38 / share ex-date Nov 21, 2025 · pay Dec 12, 2025 | 2025-11-21 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Amgen Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.